Summary: Climate changes resulting from anthropogenic impact re-quire an active response from the international community. The reduction of greenhouse gas emissions complies with the applicable legal regulations. The concept of carbon footprint makes it possible to identify activities, processes or products that potentially have a large impact on trends in climate change. In general, healthcare is responsible for around 10%, of which medical aerosols account for around 0.03% of greenhouse gas emissions. About 800 million pressurized pMDI inhalers containing 11,500 tons of HFA carrier are sold annually, with an estimated carbon footprint of 13 million tons of CO2. When analyzing different types of inhalers, it is clear that the carbon footprint mainly depends on the type of inhaler and not on the active substance. The carbon footprint of a powder inhaler is approximately 10‒50 times lower compared to the corresponding pMDI. In everyday clinical practice, the choice of the type of inhaler should take into account the availability of the active substance, the patientʼs ability to use a given type of inhaler, the price of the drug, and the potential impact of the inhaler on global warming. Other recommended activities include the introduction of new types of carriers, the use of products combined in one package, education in the inhalation technique and treatment regimen, optimization of the use of existing inhalers and the development of effective methods of recycling all types of inhalers. This is part of the coordinated activities of the international community, whose experts emphasize the importance of active measures to stop global warming and its consequences.